Merck & Co., Inc. $MRK Shares Sold by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA reduced its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 11.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 42,549 shares of the company’s stock after selling 5,624 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Merck & Co., Inc. were worth $4,479,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Darwin Wealth Management LLC grew its holdings in Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after acquiring an additional 216 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $27,000. Barnes Dennig Private Wealth Management LLC lifted its position in shares of Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after purchasing an additional 266 shares during the last quarter. Bare Financial Services Inc lifted its position in shares of Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Finally, United Financial Planning Group LLC acquired a new position in Merck & Co., Inc. in the third quarter worth about $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Merck & Co., Inc.

In related news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Chirfi Guindo sold 20,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the transaction, the chief marketing officer owned 80,615 shares in the company, valued at approximately $9,825,356.20. This represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 320,176 shares of company stock worth $38,281,735 over the last ninety days. 0.13% of the stock is currently owned by insiders.

Merck & Co., Inc. Stock Down 0.0%

Merck & Co., Inc. stock opened at $114.17 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The firm’s fifty day simple moving average is $115.81 and its 200-day simple moving average is $100.65. The company has a market capitalization of $282.27 billion, a P/E ratio of 15.68, a P/E/G ratio of 2.21 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter in the prior year, the business earned $1.72 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 16th will be given a dividend of $0.85 per share. The ex-dividend date is Monday, March 16th. This represents a $3.40 annualized dividend and a yield of 3.0%. Merck & Co., Inc.’s dividend payout ratio is 46.70%.

Analyst Upgrades and Downgrades

MRK has been the subject of several research reports. Deutsche Bank Aktiengesellschaft upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research report on Friday, February 13th. Cantor Fitzgerald increased their price objective on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 target price for the company in a research note on Thursday, January 8th. Finally, Citigroup upped their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $127.13.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.